Yun Ku Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yun Ku Cho has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Mi Young Kim
Department of Radiology, VHS Medical Center, Seoul, Korea
8 shared publicationsJae Kyun Kim
Department of Radiology, Chung‐Ang University College of Medicine, Seoul, Korea
6 shared publications- Jin Wook Chung
Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
5 shared publications Wan Tae Kim
Department of Radiology, Seoul Veterans Hospital, Seoul, Korea
4 shared publicationsHyunchul Rhim
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3 shared publicationsYong-Sik Ahn
Department of Radiology, Seoul Veterans Hospital, Seoul 134-060, Korea
3 shared publications
Latest Publications
- Open Access
- 15 January 2018
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 12 (1) , 79-85
Non-hypervascular Hypointense Nodules on Hepatocyte Phase Gadoxetic Acid-Enhanced MR Images: Transformation of MR Hepatobiliary Hypointense Nodules into Hypervascular Hepatocellular Carcinomas
Yun Ku Cho, Ju Won Kim, Mi Young Kim, and Hyeon Je Cho. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl17046
- 15 January 2018
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 12 (1) , 79-85
Open AccessNon-hypervascular Hypointense Nodules on Hepatocyte Phase Gadoxetic Acid-Enhanced MR Images: Transformation of MR Hepatobiliary Hypointense Nodules into Hypervascular Hepatocellular Carcinomas
Yun Ku Cho, Ju Won Kim, Mi Young Kim, and Hyeon Je Cho. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl17046
- Open Access
- 1 January 2018
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 79 (5) , 264-270
Tumor Recurrence in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: Portal Hypertension as an Indicator of Recurrence of Hepatocellular Carcinoma
Jang SW, et al. J Korean Soc Radiol. 2018 Nov;79(5):264-270. https://doi.org/10.3348/jksr.2018.79.5.264
- 1 January 2018
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 79 (5) , 264-270
Open AccessTumor Recurrence in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: Portal Hypertension as an Indicator of Recurrence of Hepatocellular Carcinoma
Jang SW, et al. J Korean Soc Radiol. 2018 Nov;79(5):264-270. https://doi.org/10.3348/jksr.2018.79.5.264
- Open Access
- 1 January 2017
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 76 (3) , 179-186
Analysis of Factors Affecting Local Tumor Progression of Colorectal Cancer Liver Metastasis after Radiofrequency Ablation
Jeon SH, et al. J Korean Soc Radiol. 2017 Mar;76(3):179-186. https://doi.org/10.3348/jksr.2017.76.3.179
- 1 January 2017
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 76 (3) , 179-186
Open AccessAnalysis of Factors Affecting Local Tumor Progression of Colorectal Cancer Liver Metastasis after Radiofrequency Ablation
Jeon SH, et al. J Korean Soc Radiol. 2017 Mar;76(3):179-186. https://doi.org/10.3348/jksr.2017.76.3.179
- Open Access
- 1 January 2017
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 77 (4) , 229-236
Liver Abscess Formation after Radiofrequency Ablation of Hepatocellular Carcinoma
Kim J, et al. J Korean Soc Radiol. 2017 Oct;77(4):229-236. https://doi.org/10.3348/jksr.2017.77.4.229
- 1 January 2017
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 77 (4) , 229-236
Open AccessLiver Abscess Formation after Radiofrequency Ablation of Hepatocellular Carcinoma
Kim J, et al. J Korean Soc Radiol. 2017 Oct;77(4):229-236. https://doi.org/10.3348/jksr.2017.77.4.229
- Open Access
- 1 January 2014
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 70 (2) , 111-118
Radiofrequency Ablation of Hepatocellular Carcinoma Located in the Liver Dome Under Intermittent CT Fluoroscopy Guidance
- 1 January 2014
- Published by The Korean Society of Radiology in Journal of the Korean Society of Radiology
- Vol. 70 (2) , 111-118
Open AccessRadiofrequency Ablation of Hepatocellular Carcinoma Located in the Liver Dome Under Intermittent CT Fluoroscopy Guidance
- Open Access
- 1 October 2013
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 32 (10) , 1703-1709
Size Discrepancy Between Sonographic and Computed Tomographic/Magnetic Resonance Imaging Measurement of Hepatocellular Carcinoma
Objectives There is no standardized method for size measurement of hepatocellular carcinoma. The purpose of this study was to evaluate whether the size and stage of hepatocellular carcinoma differ according to the imaging modality. Methods This retrospective study was approved by our Institutional Review Board, and written informed consent was waived. Patients with hepatocellular carcinoma who underwent either computed tomography (CT) or magnetic resonance imaging (MRI) along with planning sonography for radiofrequency ablation on the same day were included. A total of 113 patients with 127 hepatocellular carcinomas were included. The sizes of the tumors were measured and the tumor stages were assessed on CT/MRI and sonography. The results were compared by a t test, Bland‐Altman limits of agreement, and a McNemar test. Results There was a significant difference in the hepatocellular carcinoma size between CT/MRI and sonographic measurements (mean difference, 0.26 cm; P < .0001). The sizes of 102 tumors (80.3%) were larger on sonography than on CT/MRI. Twelve tumors (9.5%) were the same size and 13 (10.2%) were smaller on sonography than on CT/MRI. There was also difference in the tumor stage (very early or not) between CT/MRI and sonography (P= .006, McNemar test). The stage was discordant in 16 of 127 tumors (12.6%). Among 69 tumors at the very early stage on CT/MRI, 14 (20.3%) were beyond the very early stage on sonography. Conclusions The size of hepatocellular carcinoma measured on sonography tends to be larger than on CT/MRI; therefore, the tumor stage can differ between sonography and CT/MRI.
- 1 October 2013
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 32 (10) , 1703-1709
Open AccessSize Discrepancy Between Sonographic and Computed Tomographic/Magnetic Resonance Imaging Measurement of Hepatocellular Carcinoma
Objectives There is no standardized method for size measurement of hepatocellular carcinoma. The purpose of this study was to evaluate whether the size and stage of hepatocellular carcinoma differ according to the imaging modality. Methods This retrospective study was approved by our Institutional Review Board, and written informed consent was waived. Patients with hepatocellular carcinoma who underwent either computed tomography (CT) or magnetic resonance imaging (MRI) along with planning sonography for radiofrequency ablation on the same day were included. A total of 113 patients with 127 hepatocellular carcinomas were included. The sizes of the tumors were measured and the tumor stages were assessed on CT/MRI and sonography. The results were compared by a t test, Bland‐Altman limits of agreement, and a McNemar test. Results There was a significant difference in the hepatocellular carcinoma size between CT/MRI and sonographic measurements (mean difference, 0.26 cm; P < .0001). The sizes of 102 tumors (80.3%) were larger on sonography than on CT/MRI. Twelve tumors (9.5%) were the same size and 13 (10.2%) were smaller on sonography than on CT/MRI. There was also difference in the tumor stage (very early or not) between CT/MRI and sonography (P= .006, McNemar test). The stage was discordant in 16 of 127 tumors (12.6%). Among 69 tumors at the very early stage on CT/MRI, 14 (20.3%) were beyond the very early stage on sonography. Conclusions The size of hepatocellular carcinoma measured on sonography tends to be larger than on CT/MRI; therefore, the tumor stage can differ between sonography and CT/MRI.
- 1 November 2011
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 254 (5) , 838-839
A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection For HCC Conforming to the Milan Criteria
- 1 November 2011
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 254 (5) , 838-839
A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection For HCC Conforming to the Milan Criteria
- 25 August 2011
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 26 (9) , 1354-1360
Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: A systematic review
Background and Aim: Surgery is the standard treatment option for hepatocellular carcinoma (HCC) meeting the Milan criteria, defined as single HCC ≤ 5 cm in maximum diameter or up to three nodules ≤ 3 cm. However, favorable survival outcomes have also been reported for these HCCs following radiofrequency ablation (RFA).Methods: We performed a systematic review to compare the results of hepatic resection and percutaneous RFA as a primary treatment option of HCC meeting the Milan criteria. Studies were identified by searching MEDLINE on PubMed, the Cochrane Library database and CANCERLIT using appropriate key words.Results: In all six identified observational studies, there were no statistically significant differences in overall survival rates between the two treatment modalities. The results of two randomized trials are controversial, while the power of these randomized trials is too limited to reach a reliable conclusion. In practice, the choice of treatment between surgery and RFA largely depends on the relationship between the local recurrence and perioperative mortality rates of HCC patients. Following RFA, local recurrence rates are low when a minimal safety margin ≥ 4–5 mm is achieved. A previous simulation study of overall survival for very early stage HCC, defined as an asymptomatic solitary small HCC ≤ 2 cm, showed that primary RFA with a 9% local recurrence rate is comparable to surgical resection with a 3% operative mortality rate.Conclusion: Acquisition of a sufficient safety margin seems to be a critical factor before recommending wider application of RFA as primary treatment for HCCs that meet the Milan criteria.
- 25 August 2011
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 26 (9) , 1354-1360
Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: A systematic review
Background and Aim: Surgery is the standard treatment option for hepatocellular carcinoma (HCC) meeting the Milan criteria, defined as single HCC ≤ 5 cm in maximum diameter or up to three nodules ≤ 3 cm. However, favorable survival outcomes have also been reported for these HCCs following radiofrequency ablation (RFA).Methods: We performed a systematic review to compare the results of hepatic resection and percutaneous RFA as a primary treatment option of HCC meeting the Milan criteria. Studies were identified by searching MEDLINE on PubMed, the Cochrane Library database and CANCERLIT using appropriate key words.Results: In all six identified observational studies, there were no statistically significant differences in overall survival rates between the two treatment modalities. The results of two randomized trials are controversial, while the power of these randomized trials is too limited to reach a reliable conclusion. In practice, the choice of treatment between surgery and RFA largely depends on the relationship between the local recurrence and perioperative mortality rates of HCC patients. Following RFA, local recurrence rates are low when a minimal safety margin ≥ 4–5 mm is achieved. A previous simulation study of overall survival for very early stage HCC, defined as an asymptomatic solitary small HCC ≤ 2 cm, showed that primary RFA with a 9% local recurrence rate is comparable to surgical resection with a 3% operative mortality rate.Conclusion: Acquisition of a sufficient safety margin seems to be a critical factor before recommending wider application of RFA as primary treatment for HCCs that meet the Milan criteria.
- Open Access
- 2 December 2010
- Published by Wolters Kluwer Health in Hepatology
- Vol. 54 (6) , 2005-2011
Radiofrequency ablation of high-grade dysplastic nodules
High-grade dysplastic nodules (HGDNs) are known to be premalignant lesions of hepatocellular carcinoma (HCC). We devised a model to estimate the long-term survival benefit of treating HGDNs by radiofrequency ablation (RFA) (Group I), as compared with regular follow-up and timely treatment by resection (Group II). A hypothetical 60-year-old compensated patient with cirrhosis was assumed. The system being modeled was assumed to be a simple Markov process, and state transition probabilities were given as parameters. Data used for simulation were obtained by a systematic review of the literature. The reported overall malignant transformation rates of HGDNs ranged from 12.5% to 80.8%, and were assumed to be 20%, 50%, and 80% using the best, moderate, and worst scenarios for Group II, respectively. The 5-year overall survival benefit of Group I compared with Group II was calculated by summing the detrimental effect of overtreatment and the beneficial effects of avoiding operative mortality. When the overall malignant transformation rate was set at 20%, 50%, or 80% the expected additional 5-year overall survival benefits of Group I compared with Group II were −0.05%, 0.20%, and 0.47%, respectively, and the corresponding additional 10-year overall survival benefits were 0.03%, 0.33%, and 0.55%, respectively. One-way sensitivity analysis showed that Group I was preferable to Group II in terms of 5-year overall survival when the 5-year overall malignant transformation rate was greater than 25.9%. Conclusion: No definite evidence indicates that the treatment of HGDNs by RFA provides additional long-term overall survival benefit as compared with regular follow-up and timely treatment. The findings of the present study concur with the present American Association for the Study of Liver Diseases guidelines. (Hepatology 2011 )
- 2 December 2010
- Published by Wolters Kluwer Health in Hepatology
- Vol. 54 (6) , 2005-2011
Open AccessRadiofrequency ablation of high-grade dysplastic nodules
High-grade dysplastic nodules (HGDNs) are known to be premalignant lesions of hepatocellular carcinoma (HCC). We devised a model to estimate the long-term survival benefit of treating HGDNs by radiofrequency ablation (RFA) (Group I), as compared with regular follow-up and timely treatment by resection (Group II). A hypothetical 60-year-old compensated patient with cirrhosis was assumed. The system being modeled was assumed to be a simple Markov process, and state transition probabilities were given as parameters. Data used for simulation were obtained by a systematic review of the literature. The reported overall malignant transformation rates of HGDNs ranged from 12.5% to 80.8%, and were assumed to be 20%, 50%, and 80% using the best, moderate, and worst scenarios for Group II, respectively. The 5-year overall survival benefit of Group I compared with Group II was calculated by summing the detrimental effect of overtreatment and the beneficial effects of avoiding operative mortality. When the overall malignant transformation rate was set at 20%, 50%, or 80% the expected additional 5-year overall survival benefits of Group I compared with Group II were −0.05%, 0.20%, and 0.47%, respectively, and the corresponding additional 10-year overall survival benefits were 0.03%, 0.33%, and 0.55%, respectively. One-way sensitivity analysis showed that Group I was preferable to Group II in terms of 5-year overall survival when the 5-year overall malignant transformation rate was greater than 25.9%. Conclusion: No definite evidence indicates that the treatment of HGDNs by RFA provides additional long-term overall survival benefit as compared with regular follow-up and timely treatment. The findings of the present study concur with the present American Association for the Study of Liver Diseases guidelines. (Hepatology 2011 )
- 1 April 2010
- Published by Wolters Kluwer Health in Hepatology
- Vol. 51 (4) , 1284-1290
Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma
No adequate randomized trials have been reported for a comparison between hepatic resection (HR) versus radiofrequency ablation (RFA) for the treatment of patients with very early stage hepatocellular carcinoma (HCC), defined as an asymptomatic solitary HCC Conclusion: Primary percutaneous RFA followed by HR for cases of initial local failure was nearly identical to HR for the overall survival of compensated cirrhotic patients with very early stage HCC. (HEPATOLOGY 2010.)
- 1 April 2010
- Published by Wolters Kluwer Health in Hepatology
- Vol. 51 (4) , 1284-1290
Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma
No adequate randomized trials have been reported for a comparison between hepatic resection (HR) versus radiofrequency ablation (RFA) for the treatment of patients with very early stage hepatocellular carcinoma (HCC), defined as an asymptomatic solitary HCC Conclusion: Primary percutaneous RFA followed by HR for cases of initial local failure was nearly identical to HR for the overall survival of compensated cirrhotic patients with very early stage HCC. (HEPATOLOGY 2010.)